Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steady-state pharmacokinetics of sulfasalazine delayed-release tablets in children with juvenile idiopathic arthritis
2017-000307-24Phase 4
- Sponsor
- Pfizer
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sulfasalazine in juvenile idiopathic arthritis (JIA), sponsored by Pfizer. Primary endpoints: Sulfasalazine steady-state maximum plasma concentration and Sulfasalazine steady-state predose concentration.
02
Drugs
sulfasalazine
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2017-000307-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000307-24.